Alan Pearl, MD
Psychiatry · New York, NYNPI 1255336319
Payments from drug & device makers
Across 56 payments — averaging $51.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$772
- Otsuka America Pharmaceutical, Inc.$615
- Avanir Pharmaceuticals, Inc.$513
- Lundbeck LLC$321
- Otsuka Pharmaceutical Development & Commercialization, Inc.$175
- Teva Pharmaceuticals USA, Inc.$125
- plus $378 from 4 others
What the payments were for
- Consulting fees$1756%
- Food & beverage$2,72394%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $772 |
| Otsuka America Pharmaceutical, Inc. | 7 | $615 |
| Avanir Pharmaceuticals, Inc. | 5 | $513 |
| Lundbeck LLC | 25 | $321 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $175 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Alkermes, Inc. | 1 | $120 |
| Eisai Inc. | 1 | $120 |
| Johnson & Johnson | 1 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,898 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 31 | $2,035 |
| Eszopiclone | 28 | $639 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $636 |
| Lorazepam | 65 | $582 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 15 | $524 |
| Alprazolam | 40 | $512 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 14 | $484 |
| Escitalopram Oxalate | 41 | $483 |
| Sertraline Hcl | 23 | $465 |
| Bupropion Hcl SrBupropion Hcl | 26 | $420 |
| Modafinil | 12 | $284 |
| Aripiprazole | 18 | $230 |
| Duloxetine Hcl | 20 | $213 |
| Paroxetine Hcl | 27 | $179 |
| Fluoxetine Hcl | 13 | $169 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New York
- Michael LiebowitzNew York$7.1M
- Paul EderNew York$2.7M
- Lenard AdlerNew York$1.8M
- Ram ShrivastavaNew York$1.8M
- Jonathan KaneNew York$1.8M
- Eric HollanderNew York$1.4M
- William HapworthNew York$1.3M
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Anthony ZoghbiNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.